The Colon Cancer Alliance CEO attended an FDA hearing and made a statement in support of Cologuard, a new, cutting-edge stool DNA test. This non-invasive colorectal cancer screening test will help make screening more accessible.
Brand name drugs can be significantly more expensive than generic versions. With the FDA approval of a generic version of a chemotherapy drug to treat breast and colon cancer, patients who had been receiving the brand-name version of Xeloda will be spending less for the same treatment and patients who couldn’t afford the medication can now ask their doctors if the generic version is right for them.
The ugly truth: the process of a traditional colonoscopy is pretty darn unappealing. The prep (yuk!) and idea of a scope being inserted you-know-where doesn’t set people running to the doctor – in fact, it makes some people run the other direction. But we know colon cancer screenings are essential to nipping colon cancer in the bud (or butt…) before it starts. Could CT (virtual) colonoscopy be the answer to tearing down this potential barrier to screening?
The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
